This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Regeneron opposes Amgen's motion for judgment in US antitrust case

( July 7, 2025, 20:32 GMT | Official Statement) -- MLex Summary: Amgen’s request for judgment as a matter of law rehashes the same arguments it presented to the jury and ignores the record as if the trial never happened, Regeneron told a US federal judge in an antitrust suit over cholesterol-reducing medication. It argued that nowhere does Amgen explain how — based on the post-trial record, and consistent with the court’s instructions on the rule of reason — the jury’s verdict cannot be justified based on the facts presented. See attached file....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections